×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. We are committed to safeguarding your information and ensuring the highest standards of data protection. Your trust and privacy are of utmost importance to us.

NIH begins a new trial to evaluate HIV treatment regimens in pregnant women

  823 Views

eMediNexus    25 January 2018

The National Institutes of Health (NIH) has launched a large international study - IMPAACT 2010 or VESTED (Virologic Efficacy and Safety of Antiretroviral Therapy Combinations with TAF/TDF, EFV and DTG) – to evaluate the current preferred first-line regimen (efavirenz (EFV), lamivudine (3TC) or emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) for pregnant women recommended by the World Health Organization (WHO) and two regimens containing a newer drug, dolutegravir (DTG), and either tenofovir alafenamide (TAF)… (NIH, January 24, 2018)

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.